Search

Restoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab

Hodgkin Lymphoma typically affects young men and women in their 30s. Although it is highly curable with the current combination of chemo and radiation therapy, approximately 20% of patients will not be cured with first line regimens.

Read more

Gdf -11 a new target to improve anemia in thalassemia.

 

β-thalassemias are characterized by ineffective red blood cell (RBC) production, leading to anemia, iron overload, and organ failure. As current treatment options for β-thalassemia are limited, there is a clear unmet need for alternative therapies.

Read more

Targeting the B-cell Receptor in Aggressive B-cell Lymphomas

In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib.

Read more

EHA2025 delegate services [draft]

EHA is pleased to introduce delegate services for the upcoming EHA2025 Congress—services that registered participants can use prior, during, or after the event. Special airline fare

Enjoy a discounted flight rate and join us in Milan.

Read more

Words of wisdom

Do you ever wonder what established leaders in the field would tell their younger selves? We have asked this question for you! Every month we bring to you a unique career perspective from people who have once been in your…

Read more

Granulocytes & Constitutional Marrow Failures Disorders

The Specialized Working Group (SWG) on Granulocytes and Constitutional Marrow Failure Syndromes (G&CMFS) derives from the fusion of the formerly existing SWG on Granulocyte and Monocyte Disorders with other initiatives, grown within the EHA environment, related to Constitutional Marrow Failure…

Read more

Session information—May 15, 2025

Topic'Optimizing vaccination strategies for chemotherapy patients: Bridging gaps in preventive care. '

Speaker detailsVerena PetzerSince February 2025, Dr Verena Petzer has been a specialist in internal medicine for hematology and oncology at the Medical University of Innsbruck in Austria.

Read more